Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Accumulated Depreciation (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Accumulated Depreciation for 11 consecutive years, with $56.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 6.42% to $56.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.6 million through Dec 2025, up 6.42% year-over-year, with the annual reading at $56.6 million for FY2025, 6.42% up from the prior year.
  • Accumulated Depreciation hit $56.6 million in Q4 2025 for Seres Therapeutics, roughly flat from $56.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $56.6 million in Q4 2025 to a low of $35.8 million in Q1 2021.
  • Historically, Accumulated Depreciation has averaged $47.7 million across 5 years, with a median of $48.5 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation: rose 21.17% in 2021 and later increased 2.82% in 2025.
  • Year by year, Accumulated Depreciation stood at $40.3 million in 2021, then grew by 11.85% to $45.0 million in 2022, then grew by 8.97% to $49.1 million in 2023, then grew by 8.39% to $53.2 million in 2024, then increased by 6.42% to $56.6 million in 2025.
  • Business Quant data shows Accumulated Depreciation for MCRB at $56.6 million in Q4 2025, $56.4 million in Q3 2025, and $55.3 million in Q2 2025.